AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03948360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
Study NCT00757003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Stent-graft repair of descending thoracic aorta
Description: A TAG device will be used to repair the pathology in the thoracic aorta
Study NCT02673606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 2Mg Tablet
Description: one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
Study NCT02673606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 4Mg Tablet
Description: two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
Study NCT02673606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pills
Description: inactive placebo pills
Study NCT04394481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: IV injection (1 µg/kg - 100 mL) before anesthetic induction
Study NCT04394481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)
Study NCT04394481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)
Study NCT04394481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: IV injection (0.15 mg/kg) during anesthetic induction
Study NCT04394481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV injection (0.15 mg/kg) during anesthetic induction
Study NCT01069250 — intervention group
Intervention type: OTHER
Intervention: There are no interventions in this study
Study NCT02992314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metaqil™ Oral Rinse
Description: Metaqil™ is a proprietary formulation of GRAS ingradients
Study NCT02992314 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation with out the active ingredients
Study NCT03684642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide
Description: Pharmaceutical form: solution for injection; Route of administration: SC
Study NCT03684642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Pharmaceutical form: solution for injection; Route of administration: SC
Study NCT03684642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy Metformin
Description: Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
Study NCT03684642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy Metformin
Description: Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
Study NCT04120610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FlowMet-R
Description: FlowMet-R is a noninvasive blood flow measurement.
Study NCT04120610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABI
Description: Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.
Study NCT04120610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TBI
Description: Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
Study NCT02407470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit antithymoglobulin (ATG)
Description: Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
Study NCT02407470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit antithymoglobulin (ATG)
Description: Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
Study NCT02407470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose derived mesenchymal stem cells ( AD-MSCs)
Description: Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
Study NCT02407470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AD-MSC transdifferentiated HSCs (AD-HSCs)
Description: Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
Study NCT05881174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture
Study NCT01067755 — intervention group
Intervention type: DEVICE
Intervention: LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)
Description: LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
Study NCT00265603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photochemotherapy With Transimmunization
Description: The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
Study NCT03618784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-RA Inj
Description: The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~* Dose level 1: 5.0 x 10\^7 cells /body 3 repeated intravenous injection at 4 week intervals~* Dose level 2: 1.0 x 10\^8 cells /body 3 repeated intravenous injection at 4 week intervals
Study NCT03618784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: sterile saline 3 repeated intravenous injection at 4 week intervals~Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.
Study NCT02179671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib once daily followed by MEDI4736
Study NCT02179671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 once daily followed by MEDI4736
Study NCT02179671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib+Docetaxel
Description: Selumetinib twice daily + docetaxel, followed by MEDI4736
Study NCT02179671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab every 4 weeks followed by MEDI4736
Study NCT03277326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: ISB block with 0.5% ropivicaine 15mls ( 45mg )
Study NCT03277326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aSSB
Description: aSSB block with 0.5% ropivicaine 15mls ( 45mg )
Study NCT03277326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pSSB
Description: pSSB block with 0.5% ropivicaine 15mls ( 45mg )
Study NCT03602274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic function monitoring
Description: AST, ALT, GGT, AP, Bilirubin
Study NCT03602274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nutritional status assesment
Description: PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
Study NCT03602274 — intervention group
Intervention type: OTHER
Intervention: Biomarker research sampling
Description: Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
Study NCT04118296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Acne Preparations for Topical Use
Description: Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
Study NCT01141088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral stent-in-stent insertion
Description: Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
Study NCT01141088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral stent-in-stent insertion
Description: Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
Study NCT03583892 — intervention group
Intervention type: DRUG
Intervention: Gabapentin
Description: One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
Study NCT00831181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
Study NCT01141088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral side-by-side insertion
Description: Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
Study NCT01141088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral side-by-side insertion
Description: Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
Study NCT00839943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozone, 0.4 ppm
Description: 2 hour ozone exposure, 0.40 ppm
Study NCT02052063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stapled transanal rectal resection
Description: transanal rectal resection using staple will be done for rectocele
Study NCT02052063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal compliance measure with Endoflip system
Description: Anal compliance will be measured using Endoflip system
Study NCT04418544 — intervention group
Intervention type: DEVICE
Intervention: Device used to record voice for screening
Description: voice recording
Study NCT05099653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: physical activity
Study NCT02714257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care plus Exercise Coaching
Description: For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.~Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.~For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation.
Study NCT04578886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.
Study NCT04578886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
Study NCT03020238 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: BiClamp group
Description: electric energy
Study NCT03020238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water jet group
Description: water jet energy
Study NCT01028950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT01638091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ex vivo module
Description: Pre-test, ex vivo computerized training module, post-test
Study NCT01638091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo practice-base learning phase
Description: Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
Study NCT03407651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
Study NCT03392272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using of Tisseel fibrin glue
Description: Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
Study NCT03392272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using sutures
Description: Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
Study NCT04695392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R2 Bundle
Description: During the intervention phase subjects will receive R2.~1. Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~2. Cycled day-night lighting and modulation of sound to match the child's routine,~3. Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~4. Night fasting with bolus enteral daytime feedings,~5. Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~6. Continuity in nursing care, and~7. Parent diaries.
Study NCT00521053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10 (10% rose bengal disodium)
Description: Intralesional injection for chemoablation
Study NCT01034540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POM3
Description: 4 g/day
Study NCT01034540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule, 4 g/day
Study NCT04115826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per-oral Pancreatoscopy-guided Lithotripsy
Description: Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
Study NCT04115826 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal Shock-Wave Lithotripsy
Description: ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
Study NCT03663881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Et extract
Description: P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
Study NCT02465385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
Study NCT02149212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotonic
Description: Aminaftone -- 75 mg BID
Study NCT02149212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Iliac Vein Stenting
Study NCT02149212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limb elastic compression support
Description: CEAP 3-5 > 20-30 mmHg compression stockings CEAP 6 > elastic bandages
Study NCT02149212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unna boot dressing
Description: CEAP 6 > Unna boot dressing
Study NCT03759483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI diagnostic algorithm
Description: The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
Study NCT04607928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
Study NCT04607928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
Study NCT04420650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal or cathodal transcranial direct current stimulation
Study NCT04420650 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal or cathodal transcranial direct current stimulation
Study NCT04688723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran + Ticagrelor
Description: Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
Study NCT04688723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran + clopidogrel
Description: Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
Study NCT03005951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A= Yes Breakfast
Description: Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
Study NCT03005951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B=No Breakfast
Description: Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.